ConcertAI, an oncology-focused AI and real-world data company, has transformed CancerLinQ, a platform originally launched by the American Society of Clinical Oncology (ASCO), into a point-of-care oncology intelligence platform. The initiative pools electronic health record data from oncology practices, turning routine patient encounters into a learning system for improved clinical decision-making.
The platform aggregates real-world data from thousands of patients, allowing oncologists to access insights at the point of care. This approach aims to bridge the gap between clinical trial results and everyday practice, enabling personalized treatment recommendations based on aggregated patient outcomes and treatment patterns.
CancerLinQ was originally conceived over a decade ago by ASCO to harness electronic health records for continuous learning. ConcertAI acquired the platform from ASCO and has since integrated it with its own AI capabilities to deliver actionable intelligence directly to clinicians, though specific acquisition terms and current patient data volumes were not disclosed.
The deal underscores the growing value of real-world evidence in oncology, as healthcare systems and drug developers seek to improve therapeutic outcomes. ConcertAI's move positions it at the intersection of AI, data aggregation, and clinical practice, though the platform's reliance on retrospective data may limit its ability to predict novel drug responses.
While the platform offers potential to democratize oncology insights, some experts caution that real-world data can contain biases from fragmented record-keeping and variable treatment standards. ConcertAI has not yet published independent validation studies comparing its platform's recommendations to standard care outcomes, leaving questions about its clinical impact unanswered.